Hec1在膀胱癌组织中的表达及其与临床病理因素和预后的关系

 目的 观察肿瘤高表达蛋白(high expression in cancer,Hec1)在人膀胱癌组织中的表达及其与临床病理因素和预后的关系。方法 运用免疫组织化学和Western印迹法检测手术切除的105例人膀胱癌及20例癌旁正常膀胱组织病理标本中Hec1的表达,其中按Elson and Ellis半定量三级分类法:Ⅰ级51例,Ⅱ级39例,Ⅲ级15例;临床TNM分期Ⅰ期31例,Ⅱ期23例,Ⅲ+Ⅳ期51例;伴淋巴结转移者71例,无淋巴结转移34例;肿瘤直径≤2 cm者49例,2～5cm 者35例,>5 cm者21例。采用Prism6.0统计软件分析肿瘤组织Hec1与临床病理因素及5年生存率的关系。采用Cox比例风险模型多因素分析影响膀胱癌预后的独立因子。结果 Hec1在人膀胱癌组织及癌旁正常组织表达率分别为78.2%(82/105)和15.0%(3/20),两者比较差异有统计学意义(P<0.01);Hec1的表达与患者的年龄、组织类型、肿瘤大小均无显著相关性(P分别为0.25, 0.17,0.26)。随临床分期的升级(P=0.042)、淋巴结转移的出现(P=0.033),Hec1表达水平逐渐增高,各组间有显著相关性;Hec1表达阳性的膀胱癌患者,术后5年生存率明显较Hec1表达阴性者低(P=0.025);淋巴结转移、TNM分期及Hec1是影响膀胱癌预后的独立因素。结论 Hec1的表达与膀胱癌的发生、发展和转归有一定相关性,有可能起到肿瘤刺激因子的作用,为临床诊断、治疗及判断预后提供方向。

Expression of Hec-1 in bladder cancer and its clinical significance

Objective To investigate the expression of highly expressed protien in cancer (Hec1) in human bladder cancer and its relationship with clinicopathological factors and prognosis.Methods Immunohistochemistry and Western blot were used to detect the expression of Hec1 in 105 cases of surgically resected human bladder cancer and 20 para-carcinoma normal bladder histopathological specimens. Clinical TNM stage Ⅰ included 31 cases of metastasis and 34 cases without lymph node metastasis. Tumor diameter was 2 cm or less in 49 patients, and 2-5 cm in 35 cases. Twenty-three cases were in stage Ⅱ and 51 cases in stages Ⅲ+Ⅳ. There were 71 cases with lymph node metastasis, and tumor diameter was above 5 cm in 21 patients. The relationship between Hec1, clinicopathological factors and 5-year survival was analyzed by Prism6.0. The Cox proportional hazard model was used to analyze the independent prognostic factors of bladder cancer.Results Hec1 was significantly higher in human bladder cancer than that in para-cancer normal tissue (P<0.01). Hec1 was not significantly correlated with age, the histological type or tumor size(P values were 0.25, 0.17 and 0.26, respectively). However, the level of Hec1 increased with the clinical staging (P=0.042) and lymph node metastasis (P=0.033). The survival rate of Caveolin-1 in bladder cancer patients was lower than that of Hec1 patients (P=0.025). Lymph node metastasis, TNM stage and Hec1 were independent prognostic factors for bladder cancer.Conclusions Hec1 may play the role of a tumor stimulating factor and can facilitate clinical diagnosis, treatment and prognosis.